Table 2 Characteristics of brain metastases according to breast cancer subtype and trastuzumab treatment before brain metastases development
From: Clinical implication of Time To Brain Metastasis (TTBM) according to breast cancer subtypes
HR-positive/HER2-negative (N=45) | HER2-positive | TNBC†(N=58) | P-value | ||
|---|---|---|---|---|---|
Without T*(N=39) | With T*(N=47) | ||||
Age, median (range) | |||||
At initial distant mets | 49 (30–85) | 45 (25–68)) | 46 (33–66) | 44 (26–65) | 0.145 |
At BM diagnosis | 51 (30–87) | 46 (26–70) | 50 (34–67) | 45 (26–67) | 0.005 |
Stage at initial diagnosis | 0.088 | ||||
I/II | 27 (61%) | 14 (38%) | 15 (30%) | 25 (43%) | |
III | 11 (23%) | 19 (48%) | 22 (48%) | 24 (41%) | |
IV | 4 (9%) | 1 (2%) | 7 (15%) | 6 (10%) | |
unknown | 3 (7%) | 5 (12%) | 3 (7%) | 3 (5%) | |
Brain as initial metastatic site | 9 (21%) | 15 (37%) | 10 (21%) | 22 (38%) | 0.112 |
Brain,the only metastatic site | 5 (11%) | 4 (10%) | 6 (13%) | 12 (21%) | 0.142 |
Site of initial distant metastasis | |||||
Bone | 18 (47%) | 18 (50%) | 15 (44%) | 21 (38%) | 0.705 |
Lung | 14 (37%) | 14 (39%) | 11 (32%) | 26 (47%) | 0.535 |
Liver | 5 (13%) | 6 (17%) | 13 (38%) | 8 (15%) | 0.036 |
Pleura | 7 (18%) | 5 (13%) | 5 (16%) | 8 (15%) | 0.936 |
LMS‡ at BM diagnosis | 7 (17%) | 6 (15%) | 6 (16%) | 12 (21%) | 0.824 |
ECOG PS at BM diagnosis | 0.482 | ||||
0-1 | 32 (72%) | 27 (69%) | 33 (70%) | 35 (60%) | |
2 | 5 (12%) | 6 (16%) | 10 (22%) | 13 (22%) | |
3-4 | 8 (19%) | 5 (14%) | 4 (9%) | 10 (17%) | |
Number of brain metastasis | 0.430 | ||||
1 | 16 (36%) | 10 (26%) | 8 (17%) | 17 (29%) | |
2-3 | 3 (7%) | 8(21%) | 8 (17%) | 9 (16%) | |
≥3 | 24 (53%) | 20 (51%) | 31 (66%) | 31 (53%) | |
missing | 2 (4%) | 1(3%) | 0(0%) | 1 (2%) | |
Extracranial systemic control at BM diagnosis | 0.122 | ||||
PR/SD | 7 (16%) | 6 (15%) | 16 (34%) | 9 (16%) | |
PD | 27 (60%) | 25 (64%) | 20 (43%) | 37 (64%) | |
No other systemic mets. | 5 (11%) | 4 (10%) | 6 (13%) | 12 (21%) | |
unknown | 6 (13%) | 4 (10%) | 5 (11%) | 0 (0%) | |